Next Article in Journal
Systemic Cancer Therapy Does Not Significantly Impact Early Vaccine-Elicited SARS-CoV-2 Immunity in Patients with Solid Tumors
Previous Article in Journal
Percentages of Vaccination Coverage Required to Establish Herd Immunity against SARS-CoV-2
Previous Article in Special Issue
Advances in Engineered Polymer Nanoparticle Tracking Platforms towards Cancer Immunotherapy—Current Status and Future Perspectives

A Review of Different Vaccines and Strategies to Combat COVID-19

School of Bio and Chemical Engineering, Sathyabama Institute of Science and Technology, Sholinganallur, Rajiv Gandhi Salai, Chennai 600119, India
Department of Biomedical Sciences, Chonnam National University Medical School, Gwangju 58128, Korea
Biomedical Science Graduate Program (BMSGP), Chonnam National University, Gwangju 58128, Korea
Department of Biotechnology, School of Biosciences and Technology, Vellore Institute of Technology, Vellore 632014, India
School of Bioscience, Faculty of Medicine, Bioscience and Nursing, MAHSA University, Jalan SP2, Bandar Saujana Putra, Jenjarom 42610, Malaysia
Department of Chemical and Biological Engineering, Iowa State University, Ames, IA 50011, USA
Centre for Materials Engineering and Regenerative Medicine, Bharath Institute of Higher Education and Research, Selaiyur 600073, India
Authors to whom correspondence should be addressed.
Academic Editor: S. Louise Cosby
Vaccines 2022, 10(5), 737;
Received: 24 March 2022 / Revised: 5 May 2022 / Accepted: 5 May 2022 / Published: 9 May 2022
(This article belongs to the Special Issue Polymeric Nanovaccines for Immune Modulation)
In December 2019, an unknown viral infection emerged and quickly spread worldwide, resulting in a global pandemic. This novel virus caused severe pneumonia and acute respiratory distress syndrome caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). It has caused 6.25 millions of deaths worldwide and remains a major concern for health, society, and the economy. As vaccination is one of the most efficient ways to combat this pandemic, different vaccines were developed in a short period. This review article discusses how coronavirus affected the top nations of the world and the vaccines being used for the prevention. Amongst the vaccines, some vaccines have already been approved, and some have been involved in clinical studies. The article also provides insight into different COVID-19 vaccine platforms, their preparation, working, efficacy, and side effects. View Full-Text
Keywords: SARS-CoV-2 infection; polymeric nanovaccine; humoral immunity; cell-mediated immunity SARS-CoV-2 infection; polymeric nanovaccine; humoral immunity; cell-mediated immunity
Show Figures

Figure 1

MDPI and ACS Style

Sabitha, S.; Shobana, N.; Prakash, P.; Padmanaban, S.; Sathiyashree, M.; Saigeetha, S.; Chakravarthi, S.; Uthaman, S.; Park, I.-K.; Samrot, A.V. A Review of Different Vaccines and Strategies to Combat COVID-19. Vaccines 2022, 10, 737.

AMA Style

Sabitha S, Shobana N, Prakash P, Padmanaban S, Sathiyashree M, Saigeetha S, Chakravarthi S, Uthaman S, Park I-K, Samrot AV. A Review of Different Vaccines and Strategies to Combat COVID-19. Vaccines. 2022; 10(5):737.

Chicago/Turabian Style

Sabitha, Srinivasan, Nagarajan Shobana, Pandurangan Prakash, Sathiyamoorthy Padmanaban, Mahendran Sathiyashree, Subramanian Saigeetha, Srikumar Chakravarthi, Saji Uthaman, In-Kyu Park, and Antony V. Samrot. 2022. "A Review of Different Vaccines and Strategies to Combat COVID-19" Vaccines 10, no. 5: 737.

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

Back to TopTop